EPHA2 and neoplasm: By targeting EphA2-expressing tumor cells, these treatments likely disrupt downstream signaling and induce cell death, but they may also coincidentally reduce the infiltration of immunosuppressive myeloid populations and increase the infiltration and activity of T cells based on our findings.